» Articles » PMID: 9845526

The Human Poliovirus Receptor Related 2 Protein is a New Hematopoietic/endothelial Homophilic Adhesion Molecule

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1998 Dec 9
PMID 9845526
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

We have recently described Poliovirus Receptor Related 2 (PRR2), a new cell surface molecule homologous to the poliovirus receptor (PVR/CD155). Both molecules are transmembrane glycoproteins belonging to the Ig superfamily (IgSF). They contain 3 Ig domains of V, C2, and C2 types in their extracellular regions that share 51% aa identity. The PRR2 gene encodes two mRNA isoforms of 3.0 kb (hPRR2 [short form]) and 4.4 kb (hPRR2delta [long form]), both widely expressed in human tissues, including hematopoietic cells. To further characterize PRR2 expression during hematopoiesis and to analyze its function, we have developed a monoclonal antibody (MoAb) directed against its extracellular region (R2.477). PRR2 was expressed in 96% of the CD34(+), 88% of the CD33(+), and 95% of the CD14(+) hematopoietic lineages and faintly in the CD41 compartment. Ectopic expression of both PRR2 cDNAs induced marked cell aggregation. A soluble chimeric receptor construct with the Fc fragment of human IgG1 (PRR2-Fc) as well as a fab fragment of the anti-PRR2 MoAb (R2.477) inhibit aggregation. PRR2-Fc binds specifically to PRR2-expressing cells. These results suggest that PRR2 is a homophilic adhesion receptor. PRR2 was also expressed at the surface of endothelial cells at the intercellular junctions of adjacent cells but not at the free cellular edges. Homophilic interactions are associated with dimerization of isoforms of PRR2 and lead to the tyrosine phosphorylation of PRR2delta. Altogether, these results suggest that homophilic properties of PRR2 could participate to the regulation of hematopoietic/endothelial cell functions.

Citing Articles

The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy.

Murakami K, Ganguly S Front Immunol. 2024; 15:1441730.

PMID: 39156900 PMC: 11327090. DOI: 10.3389/fimmu.2024.1441730.


Therapeutic prospects of nectin-4 in cancer: applications and value.

Li K, Zhou Y, Zang M, Jin X, Li X Front Oncol. 2024; 14:1354543.

PMID: 38606099 PMC: 11007101. DOI: 10.3389/fonc.2024.1354543.


PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways.

Yang J, Wang L, Byrnes J, Kirkemo L, Driks H, Belair C Cancer Immunol Res. 2024; 12(5):575-591.

PMID: 38588410 PMC: 11063765. DOI: 10.1158/2326-6066.CIR-23-0722.


Immune cell-related prognostic risk model and tumor immune environment modulation in esophageal carcinoma based on single-cell and bulk RNA sequencing.

Wen X, Pu L, Wencheng Z, Tengfei M, Guangshun W Thorac Cancer. 2024; 15(14):1176-1186.

PMID: 38587029 PMC: 11091786. DOI: 10.1111/1759-7714.15301.


The co-inhibitory receptor TIGIT regulates NK cell function and is upregulated in human intrahepatic CD56 NK cells.

Ziegler A, Fittje P, Muller L, Ahrenstorf A, Hagemann K, Hagen S Front Immunol. 2023; 14:1117320.

PMID: 36845105 PMC: 9948018. DOI: 10.3389/fimmu.2023.1117320.